Moderna, Inc.
MRNAModerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +29.2%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +13,550.0%
Quarter to September 2026, against a year earlier
After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.
Follow MRNA
Alert me
Moderna, Inc. (MRNA) Revenue growth
Moderna, Inc.'s revenue growth over the twelve months to Sep 30, 2026 was 13.1%, up 53.1 percentage points from fiscal 2025 (−39.9%). Over the past ten years it has ranged from −64.5% (fiscal 2023) to 2,200.3% (fiscal 2021); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of 7.20% and above the Healthcare sector median of 8.62%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −39.9% | 12.82 |
| FY2024 | −52.8% | 11.70 |
| FY2023 | −64.5% | (68.74) |
| FY2022 | 4.29% | (2,195.96) |
| FY2021 | 2,200.3% | 961.92 |
| FY2020 | 1,238.3% | 1,293.91 |
| FY2019 | −55.6% | (21.20) |
| FY2018 | −34.4% | (124.26) |
| FY2017 | 89.9% | 137.26 |
| FY2016 | −47.4% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 29.2% | 27.12 |
| Jun 2026 | 2.11% | (258.08) |
| Mar 2026 | 260.2% | 290.00 |
| Dec 2025 | −29.8% | 15.63 |
| 31 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RVMD Revolution Medicines, Inc. compare | 491.1% |
| INSM Insmed, Inc. compare | 240.0% |
| ARGX argenex SE compare | 60.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 32.9% |
| GMAB Genmab A/S Sponsored ADR compare | 19.8% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 18.6% |
| MRNA Moderna, Inc. | 13.1% |
| RPRX Royalty Pharma PLC compare | 11.4% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 10.5% |
| Biotechnology industry median | 7.20% |
| Healthcare sector median | 8.62% |
| Market median | 7.91% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement